Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers
- PMID: 33455826
- PMCID: PMC8005459
- DOI: 10.1016/j.pec.2020.12.019
Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers
Abstract
Objective: This study explored motivators and challenges/barriers to sharing personal genetic test results (GTR) with family members (FM).
Methods: Semi-structured, in-depth interviews were conducted with 62 women who had a pathogenic or likely pathogenic (P/LP) variant in aBRCA, PALB2, CHEK2, or ATM gene. Selective qualitative data analysis focused on eliciting motivators and challenges/barriers identified by participants when sharing their GTR with FM.
Results: Motivators to sharing personal GTR with FM included: health protection and prevention; moral obligation; decisional empowerment; familial ties; written resources; and contextualization for a familial cause for cancer. Challenges/barriers to family sharing included: concern for FM reactions; complexities of information; lack of closeness; perceived relevance; and emotional impact.
Conclusions: All motivators and challenges/barriers were identified across BRCA and non-BRCA carriers, demonstrating commonalities in family sharing of GTR among high- to moderate-penetrance hereditary BC (breast cancer) genes. Despite challenges/barriers, participants disclosed their GTR with most close FM, yet restrictions in communication and/or strain on the timing, manner of disclosing, and strategies used varied across certain FM.
Practice implications: These findings offer healthcare providers and researchers preliminary practical implications for broadly improving family sharing interventions across P/LP variants in BC risk genes by demonstrating important elements to include in family sharing letters.
Keywords: Barriers; Cancer genetic test results; Challenges; Family sharing; Motivators.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors report no declarations of interest.
Similar articles
-
Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.Cancer. 2019 Aug 15;125(16):2829-2836. doi: 10.1002/cncr.32083. Epub 2019 Jun 17. Cancer. 2019. PMID: 31206626 Free PMC article.
-
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.Breast Cancer Res Treat. 2020 Jul;182(2):421-428. doi: 10.1007/s10549-020-05699-y. Epub 2020 May 22. Breast Cancer Res Treat. 2020. PMID: 32445176
-
Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.Cancer. 2020 Feb 1;126(3):549-558. doi: 10.1002/cncr.32572. Epub 2019 Nov 4. Cancer. 2020. PMID: 31682005 Free PMC article.
-
Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?Breast Cancer Res. 2008;10(3):208. doi: 10.1186/bcr2099. Epub 2008 Jun 5. Breast Cancer Res. 2008. PMID: 18557994 Free PMC article. Review.
-
[The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].Klin Onkol. 2012;25 Suppl:S59-66. Klin Onkol. 2012. PMID: 22920209 Review. Czech.
Cited by
-
Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design.Sci Rep. 2021 Oct 11;11(1):20178. doi: 10.1038/s41598-021-98737-8. Sci Rep. 2021. PMID: 34635688 Free PMC article.
-
The Communication Chain of Genetic Risk: Analyses of Narrative Data Exploring Proband-Provider and Proband-Family Communication in Hereditary Breast and Ovarian Cancer.J Pers Med. 2022 Jul 29;12(8):1249. doi: 10.3390/jpm12081249. J Pers Med. 2022. PMID: 36013197 Free PMC article.
-
Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report.Hered Cancer Clin Pract. 2021 Sep 26;19(1):40. doi: 10.1186/s13053-021-00198-7. Hered Cancer Clin Pract. 2021. PMID: 34565430 Free PMC article.
-
The Development and Evaluation of Novel Patient Educational Material for a Variant of Uncertain Significance (VUS) Result in Hereditary Cancer Genes.Curr Oncol. 2024 Jun 16;31(6):3361-3378. doi: 10.3390/curroncol31060256. Curr Oncol. 2024. PMID: 38920739 Free PMC article.
-
Health Care Equity and BRCA1/2 Testing.Health Equity. 2025 Feb 21;9(1):127-130. doi: 10.1089/heq.2024.0167. eCollection 2025. Health Equity. 2025. PMID: 40123843 Free PMC article.
References
-
- American Cancer Society, I. Breast Cancer Risk and Prevention: Breast Cancer Risk Factors You Cannot Change. 2020. [cited 2020 March 23]; Available from: https://www.cancer.org/cancer/breast-cancer/risk-and-prevention/breast-c....
-
- Kuchenbaecker KB, et al., Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 2017. 317(23): p. 2402–2416. - PubMed
-
- National Cancer Institute: Surveillance, E., and End Results Program. Cancer Stat Facts: Female Breast Cancer. 2016. [cited 2020 March 22]; Available from: https://seer.cancer.gov/statfacts/html/breast.html.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous